To establish initial clinical relevance for the in vitro observations, we tested the hypothesis that levels of nuclear localized and tyrosine phosphorylated Stat5 (Nuc-pYStat5) would be low in human breast cancer specimens expressing elevated levels of GLUT1, a glucose transporter. Here, SLC2A1 is linked to breast cancer.